Flare Therapeutics has entered into a strategic discovery collaboration with Roche. The partnership will leverage Flare Therapeutics' proteomic and mass spectrometry platform, to discover small molecule drugs aimed at previously undrugged transcription factor targets in oncology. Flare Therapeutics will lead discovery and preclinical activities targeting multiple transcription factor targets in oncology, while Roche will pursue the further preclinical and clinical development and commercialization of potential products from the collaboration.
Flare Therapeutics will receive a $70 million upfront cash payment and is eligible to receive discovery, development, and commercialization milestone payments potentially exceeding $1.8 billion and royalties. Also, Flare Therapeutics retains a right to co-fund development for one target under the collaboration in exchange for increased royalties in the United States for this target.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.